|
|
News Breaks
|
November 4, 2009
|
| 09:00 EDT |  | ENZ |
| theflyonthewall.com: | Enzo Biochem VP says oral immune regulation platform shows "therapeutic promise" | | Enzo Biochem reported on the company’s therapeutic platforms utilizing oral immune regulation for immune mediated diseases at the Bio-Europe 2009 15th Annual International Conference calling it a “bright area of therapeutic promise.” David Goldberg, Enzo's VP, Corporate Development, cited two examples of ongoing clinical studies: Alequel, an individualized therapy for treatment of Crohn’s disease: a multi-arm Phase 2 clinical trial, with no treatment-related side-effects, having met its endpoints and offering the potential to induce long-term remission. If successful, Alequel could reduce the need for steroids and immunosuppressive therapy. Optiquel, an oral, novel peptide for autoimmune uveitis: a proof of concept trial is being undertaken in conjunction with the National Eye Institute. Mr. Goldberg also noted that the company has also made progress in the development of its drug screening platform that has yielded orally delivered small molecules having potentially significant effects for bone disorders and diabetes. :theflyonthewall.com |
|
|
News For ENZ From The Last 14 Days Check below for free stories on ENZ the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
